Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POLY-RX vs ALTABAX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
POLY-RX is a fictional drug with no established mechanism of action.
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
No FDA-approved or off-label indications exist for a non-existent drug.
FDA-approved for topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes in patients aged 9 months and older
Not established. Data insufficient for dosing recommendations.
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
12-15 hours; prolonged in renal impairment (up to 30 hours); no dose adjustment needed for mild-moderate renal impairment
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
Not characterized for a non-existent drug.
Retapamulin undergoes hepatic metabolism primarily via cytochrome P450 (CYP) isoenzymes, including CYP3A4, and is excreted in feces and urine.
Renal 80% unchanged, biliary/fecal 20%
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
92% bound to albumin
Retapamulin is approximately 94% bound to human plasma proteins, primarily albumin.
0.8 L/kg; indicates moderate tissue distribution
Volume of distribution after IV administration is approximately 3.1 L/kg, indicating extensive tissue distribution.
Oral: 75% (with food decreases absorption); IM: 100%
Systemic bioavailability after topical application is low and highly variable, with mean values <2% in adults.
No data available for renal impairment.
No dose adjustment required for renal impairment as systemic absorption is negligible.
No data available for hepatic impairment.
No dose adjustment required for hepatic impairment as systemic absorption is negligible.
No established pediatric dosing.
Children 9 months and older: Apply 1% ointment to affected area twice daily for 5 days. Maximum treatment area 100 cm². For children under 9 months: safety and efficacy not established.
No specific geriatric dosing guidelines.
No specific dose adjustment required. Use same as adult dosing due to minimal systemic absorption.
None
No black box warnings.
No clinical warnings applicable to a non-existent drug.
Not for use on mucous membranes (e.g., eyes, mouth, vagina).,May cause application site reactions (e.g., pruritus, erythema, pain).,Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including retapamulin.,Prolonged use may result in overgrowth of nonsusceptible organisms.
None established for a non-existent drug.
Hypersensitivity to retapamulin or any component of the formulation.
Avoid grapefruit and grapefruit juice as it may increase levels of some components. Take with food if gastrointestinal upset occurs, but avoid high-fat meals that may alter absorption. Limit alcohol consumption as it may increase hepatotoxicity risk.
None known. Topical application with negligible systemic absorption; no dietary restrictions.
Insufficient data in humans; animal studies not available. Risk cannot be excluded; use only if benefit outweighs risk. First trimester: theoretical risk based on mechanism. Second/third trimester: unknown.
No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 times MRHD) showed no fetal harm. However, systemic absorption after topical application is minimal, so fetal exposure is negligible. Risk cannot be ruled out; classify as pregnancy category B.
No data on excretion in human milk; M/P ratio unknown. Caution advised; consider risk to infant versus benefit to mother.
Not known if retapamulin is excreted in human milk. Systemic absorption is negligible after topical use, so risk to infant is likely low. M/P ratio not determined. Caution if applied to breast area to avoid infant ingestion.
No specific dose adjustments recommended due to lack of pharmacokinetic data in pregnancy. Monitor clinical response and adjust based on tolerability.
No dose adjustment needed. Pharmacokinetics unchanged as systemic absorption is minimal (<1%) and not affected by pregnancy. Standard dosing: apply thin layer to affected area twice daily for 5 days.
POLY-RX is a multi-drug regimen; ensure adherence to all components to prevent subtherapeutic effect and resistance. Monitor renal function for all components, especially if any are renally excreted. Check for drug-drug interactions, particularly with CYP450 inducers/inhibitors. Adjust doses in hepatic or renal impairment per individual drug guidelines.
Retapamulin (Altabax) is a topical pleuromutilin antibiotic indicated for impetigo due to S. aureus or S. pyogenes. Apply to lesions twice daily for 5 days. Avoid contact with eyes, mouth, or mucous membranes. No systemic absorption significant; safe for use in children ≥9 months. Do not use on open wounds or burns. Monitor for local irritation; discontinue if hypersensitivity occurs.
Take all medications exactly as prescribed at the same time each day.,Do not skip doses or stop taking any component without consulting your doctor.,Report any signs of allergic reaction, severe nausea, or unusual bleeding.,Keep a list of all medications you take, including over-the-counter and supplements.,Store medications in a cool, dry place away from children.
Apply a thin layer to the affected area twice daily for 5 days, even if symptoms improve.,Wash hands before and after application unless treating hand lesions.,Do not cover the area with bandages unless instructed by your doctor.,Avoid getting the ointment in your eyes, nose, mouth, or on vaginal area.,Stop use and inform your doctor if you develop severe irritation, redness, or swelling.,Store at room temperature away from heat and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POLY-RX vs ALTABAX, answered by our medical review team.
POLY-RX is a Topical Antibiotic that works by POLY-RX is a fictional drug with no established mechanism of action.. ALTABAX is a Topical Antibiotic that works by Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POLY-RX and ALTABAX depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POLY-RX is: Not established. Data insufficient for dosing recommendations.. The standard adult dose of ALTABAX is: 1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POLY-RX and ALTABAX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POLY-RX is classified as Category C. Insufficient data in humans; animal studies not available. Risk cannot be excluded; use only if benefit outweighs risk. First trimester: theoretical risk based on mechanism. Second. ALTABAX is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 time. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.